MAC prophylaxis in the era of polypharmacy. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


MAC prophylaxis in the era of polypharmacy.

WMJ. 1999 May-Jun;98(3):46-8. Unique Identifier : AIDSLINE MED/99342624
Sawhney N; Infectious Disease Consultants of Wisconsin, Milwaukee 53215,; USA.

Abstract: In the advanced stages of AIDS, patients are increasingly susceptible to disseminated Mycobacterium avium-intracellulare (MAC) infection, causing significant morbidity and mortality. It has been shown that prophylaxis against this infection is effective in reducing the incidence as well as the symptoms of MAC. Although chemoprophylaxis against MAC is a standard recommendation, it is not always carried out due to a variety of reasons. Several agents are now approved for this purpose, adding to the complexity of the decision to start the prophylaxis. This article reviews the need for prophylaxis against MAC, and considers the different agents available, with the aim of helping readers come to an informed decision about starting MAC prophylaxis in their patients. This issue will be of rising importance with the effective prevention of other opportunistic infections in patients with advancing immune deficiency.
Keywords: JOURNAL ARTICLE Antibiotics, Macrolide/THERAPEUTIC USE Azithromycin/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/DRUG THERAPY/*PREVENTION & CONTROL Clarithromycin/THERAPEUTIC USE Human Mycobacterium avium-intracellulare Infection/DRUG THERAPY/ *PREVENTION & CONTROLKWDjournalarticleantibiotics,macrolide/therapeuticuseazithromycin/KWDtherapeuticuseaids-relatedopportunisticinfections/drugtherapy/KWDprevention&controlclarithromycin/therapeuticusehumanmycobacteriumavium-intracellulareinfection/drugtherapy/KWDprevention&control
991030
A99A0917

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .